HK1185874A1 - 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺 - Google Patents

用於治療癌症的新的 -氨基- -羥基-苯甲酰胺

Info

Publication number
HK1185874A1
HK1185874A1 HK13113226.4A HK13113226A HK1185874A1 HK 1185874 A1 HK1185874 A1 HK 1185874A1 HK 13113226 A HK13113226 A HK 13113226A HK 1185874 A1 HK1185874 A1 HK 1185874A1
Authority
HK
Hong Kong
Prior art keywords
benzamides
cancer
hydroxy
amino
novel
Prior art date
Application number
HK13113226.4A
Other languages
English (en)
Inventor
Xianfeng Lin
Zongxing Qiu
Guozhi Tang
Jason Christopher Wong
Zhenshan Zhang
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1185874A1 publication Critical patent/HK1185874A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
HK13113226.4A 2011-01-21 2013-11-27 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺 HK1185874A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011070464 2011-01-21
PCT/EP2012/050665 WO2012098132A1 (en) 2011-01-21 2012-01-18 Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1185874A1 true HK1185874A1 (zh) 2014-02-28

Family

ID=45497996

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13113226.4A HK1185874A1 (zh) 2011-01-21 2013-11-27 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺

Country Status (11)

Country Link
US (1) US8404738B2 (zh)
EP (1) EP2665706B1 (zh)
JP (1) JP5778297B2 (zh)
KR (1) KR101569261B1 (zh)
BR (1) BR112013017362A2 (zh)
CA (1) CA2823780A1 (zh)
ES (1) ES2525569T3 (zh)
HK (1) HK1185874A1 (zh)
MX (1) MX2013008340A (zh)
RU (1) RU2591190C2 (zh)
WO (1) WO2012098132A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827056B (zh) * 2012-09-03 2014-07-23 华东理工大学 N-芳基取代吡咯烷酮衍生物及其用途
WO2015054474A1 (en) * 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
JP6952602B2 (ja) 2014-07-07 2021-10-20 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害剤による白血病の治療
EP3268360B1 (en) 2015-03-09 2019-04-24 Bristol-Myers Squibb Company Lactams as inhibitors of rock
SG10201913192VA (en) * 2015-07-02 2020-03-30 Biomarin Pharm Inc Histone deacetylase inhibitors
WO2018089651A1 (en) 2016-11-10 2018-05-17 Acetylon Pharmaceuticals, Inc. Phenyl and pyridinyl hydroxamic acids
WO2018130155A1 (zh) * 2017-01-10 2018-07-19 南京明德新药研发股份有限公司 Hdac6选择性抑制剂及其制备方法和应用
EP3911645B1 (en) 2019-01-17 2022-12-07 Université de Lille 5-membered heteroaryl compounds containing a hydroxamate moiety and their use
EP4122494A4 (en) * 2020-03-16 2024-04-24 Mandom Corp METHOD FOR DETECTING A T-CELL LYMPHOMA INDICATOR AND USE THEREOF
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL212089B1 (pl) * 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
WO2005108367A1 (en) 2004-05-03 2005-11-17 Envivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
CA2576667A1 (en) 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
EP1861097A4 (en) * 2005-03-16 2010-01-13 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
SI2343286T1 (sl) 2006-10-28 2015-05-29 Methylgene Inc. Derivati dibenzo(b,f)(1,4) oksazepina kot inhibitorji histonske deacetilaze
US20090005374A1 (en) * 2007-06-26 2009-01-01 Melvin Jr Lawrence S Imidazopyridinyl thiazolyl histone deacetylase inhibitors
JP5670877B2 (ja) 2008-04-15 2015-02-18 ファーマサイクリックス，インク． ヒストン脱アセチル化酵素の選択的インヒビター
CA2728228A1 (en) * 2008-07-14 2010-01-21 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
WO2012075380A1 (en) * 2010-12-03 2012-06-07 The Trustees Of The University Of Pennsylvania Tip60 inhibitors

Also Published As

Publication number Publication date
KR20130120517A (ko) 2013-11-04
RU2013136412A (ru) 2015-02-27
JP2014502983A (ja) 2014-02-06
RU2591190C2 (ru) 2016-07-10
ES2525569T3 (es) 2014-12-26
CA2823780A1 (en) 2012-07-26
JP5778297B2 (ja) 2015-09-16
US20120190700A1 (en) 2012-07-26
KR101569261B1 (ko) 2015-11-13
BR112013017362A2 (pt) 2016-10-04
EP2665706B1 (en) 2014-10-22
EP2665706A1 (en) 2013-11-27
MX2013008340A (es) 2013-08-27
WO2012098132A1 (en) 2012-07-26
US8404738B2 (en) 2013-03-26

Similar Documents

Publication Publication Date Title
HK1202253A1 (zh) 癌症的聯合治療
HK1254859A1 (zh) 治療乳腺癌的方法
HK1201256A1 (zh) 用於治療癌症的吡咯並嘧啶化合物
IL228738A0 (en) Antibodies for cancer treatment
ZA201307036B (en) Treatment of solid tumours
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
HRP20160851T1 (hr) Prediktori za liječenje karcinoma
IL228430A0 (en) Cancer treatment
EP2903644A4 (en) TREATMENT OF CANCER
GB201217892D0 (en) Treatment of cancer
IL275636A (en) Medical combination for cancer treatment
EP2817011A4 (en) TREATMENT OF CANCER
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201217890D0 (en) Treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
EP2750691A4 (en) SRPX IN THE TREATMENT OF CANCER
IL229109A0 (en) Cancer diagnosis
GB201116328D0 (en) Treatment for tumours
GB201208296D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230120